Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ. Weiß, K. Dragnev, Marina Maglakelidze et al.|Annals of Oncology|2019Cited by 173